Lmcg Investments LLC Has $1.97 Million Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Lmcg Investments LLC reduced its stake in Gilead Sciences by 42.8% in Q2, leaving them with 17,797 shares valued at approximately $1.97 million.
• Gilead Sciences has received multiple upgrades from analysts, with Cantor Fitzgerald raising its price target from $129 to $135 and a large majority of analysts rating the stock as a "buy."
• The company recently declared a quarterly dividend of $0.79, corresponding to an annual yield of 2.7%, with a dividend payout ratio of 62.95%.

Lmcg Investments LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 42.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,797 shares of the biopharmaceutical company's stock after selling 13,316 shares during the quarter. Lmcg Investments LLC's holdings in Gilead Sciences were worth $1,973,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Brighton Jones LLC boosted its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences during the fourth quarter worth about $215,000. GAMMA Investing LLC boosted its holdings in Gilead Sciences by 24.9% during the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company's stock worth $2,550,000 after buying an additional 4,532 shares during the last quarter. Everhart Financial Group Inc. boosted its holdings in Gilead Sciences by 55.9% during the first quarter. Everhart Financial Group Inc. now owns 4,042 shares of the biopharmaceutical company's stock worth $453,000 after buying an additional 1,450 shares during the last quarter. Finally, Salem Investment Counselors Inc. boosted its holdings in Gilead Sciences by 345.5% during the first quarter. Salem Investment Counselors Inc. now owns 490 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 380 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on GILD shares. Weiss Ratings restated a "buy (b)" rating on shares of Gilead Sciences in a report on Wednesday. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Cantor Fitzgerald raised their target price on Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a report on Thursday. Citigroup lifted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $118.08.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Up 0.4%

NASDAQ:GILD opened at $117.18 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market capitalization of $145.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The business's 50-day simple moving average is $114.65 and its 200-day simple moving average is $110.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm earned $2.01 EPS. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.